Sophia Adamia

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression
    Sophia Adamia
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Electronic address
    Adv Cancer Res 123:67-94. 2014
  2. ncbi request reprint Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?
    Sophia Adamia
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA 02215
    Curr Cancer Drug Targets 13:735-48. 2013
  3. ncbi request reprint Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets
    Sophia Adamia
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Curr Cancer Drug Targets 13:347-61. 2013
  4. pmc The dChip survival analysis module for microarray data
    Samir B Amin
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 450 Brookline Ave, Boston, MA 02215, USA
    BMC Bioinformatics 12:72. 2011
  5. pmc NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML
    Sophia Adamia
    Medical Oncology, Dana Farber Cancer Institute, and
    Blood 123:2816-25. 2014
  6. doi request reprint Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 27:250-5. 2009
  7. doi request reprint Genetic abnormalities in Waldenström's macroglobulinemia
    Sophia Adamia
    Department of Oncology, University of Alberta, and Dana Farber Cancer Institute, Boston, MA, USA
    Clin Lymphoma Myeloma 9:30-2. 2009
  8. pmc A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets
    Sophia Adamia
    Authors Affiliations Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Bioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts Dana Farber Cancer Institute, Center for Cancer Systems Biology and Department of Genetics, Harvard Medical School, Boston University School of Medicine and Biomedical Engineering Department, Boston University, Boston, Massachusetts Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France Hematology laboratory, University Hospital and INSERM U892, Nantes, France Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, Massachusetts Biotique Systems Inc, www biotiquesystems com Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts Brigham and Women s Hospital, Boston, Massachusetts Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res 20:1135-45. 2014
  9. pmc Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
    Jana Jakubikova
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
    Blood 117:4409-19. 2011
  10. pmc Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells
    Ellen Weisberg
    Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25351. 2011

Collaborators

Detail Information

Publications11

  1. doi request reprint Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression
    Sophia Adamia
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Electronic address
    Adv Cancer Res 123:67-94. 2014
    ..We speculate that synthesis of intracellular HA plays a fundamental and early role in oncogenesis by promoting genetic instability and the emergence of viable cancer variants that lead to aggressive disease. ..
  2. ncbi request reprint Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?
    Sophia Adamia
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA 02215
    Curr Cancer Drug Targets 13:735-48. 2013
    ..Herein we discuss potential therapeutic approaches that can be used to target splicing abnormalities in CML. ..
  3. ncbi request reprint Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets
    Sophia Adamia
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Curr Cancer Drug Targets 13:347-61. 2013
    ..In conclusion, we emphasize that specific gene splice variants and the splicing process itself offer potential targets for novel drug treatment strategies...
  4. pmc The dChip survival analysis module for microarray data
    Samir B Amin
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 450 Brookline Ave, Boston, MA 02215, USA
    BMC Bioinformatics 12:72. 2011
    ..However, there is no software that can perform survival analysis using SNP array data or draw survival curves interactively for expression-based sample clusters...
  5. pmc NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML
    Sophia Adamia
    Medical Oncology, Dana Farber Cancer Institute, and
    Blood 123:2816-25. 2014
    ..Thus, splice variants of these genes might provide disease markers and targets for novel therapeutics. ..
  6. doi request reprint Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 27:250-5. 2009
    ....
  7. doi request reprint Genetic abnormalities in Waldenström's macroglobulinemia
    Sophia Adamia
    Department of Oncology, University of Alberta, and Dana Farber Cancer Institute, Boston, MA, USA
    Clin Lymphoma Myeloma 9:30-2. 2009
    ..This suggests that acquired HAS1 mutations precede frank malignancy and might contribute to the initial transforming events in WM as well as to disease progression...
  8. pmc A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets
    Sophia Adamia
    Authors Affiliations Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Bioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts Dana Farber Cancer Institute, Center for Cancer Systems Biology and Department of Genetics, Harvard Medical School, Boston University School of Medicine and Biomedical Engineering Department, Boston University, Boston, Massachusetts Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France Hematology laboratory, University Hospital and INSERM U892, Nantes, France Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, Massachusetts Biotique Systems Inc, www biotiquesystems com Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts Brigham and Women s Hospital, Boston, Massachusetts Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res 20:1135-45. 2014
    ..We investigated genome-wide splicing abnormalities in AML and based on these abnormalities, we aimed to identify novel potential biomarkers and therapeutic targets...
  9. pmc Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
    Jana Jakubikova
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
    Blood 117:4409-19. 2011
    ..Our studies demonstrate a novel mechanism of action for lenalidomide, namely targeting SP fraction, providing the framework for new therapeutic strategies targeting subpopulations of MM cells including presumptive stem cells...
  10. pmc Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells
    Ellen Weisberg
    Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25351. 2011
    ..Thus, there is a need for identification of molecular mechanisms of clinical resistance to these drugs. In response, we characterized MOLM13 AML cell lines made resistant to two structurally-independent FLT3 inhibitors...
  11. doi request reprint Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia and Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 145:59-63. 2009
    ..These data depict for the first time a heterogeneous expression pattern of the genes involved in late differentiation process of plasma cells in patients with WM and propose a role of XBP1-ERN1alpha in WM pathogenesis...